A Direct Aspiration, First Pass Technique (ADAPT) versus Stent Retrievers for Acute Stroke Therapy: An Observational Comparative Study


AJNR Am J Neuroradiol 2016, 37 (10) 1860-1865
doi: https://doi.org/10.3174/ajnr.A4840
http://www.ajnr.org/content/37/10/1860
A Direct Aspiration, First Pass Technique (ADAPT) versus Stent Retrievers for Acute Stroke Therapy: An Observational Comparative Study


ABSTRACT

BACKGROUND AND PURPOSE: Mechanical thrombectomy with stent retrievers is now the standard therapy for selected patients with ischemic stroke. The technique of A Direct Aspiration, First Pass Technique for the Endovascular Treatment of Stroke (ADAPT) appears promising with a high rate of recanalization. We compared ADAPT versus stent retrievers (the Solitaire device) for efficacy and safety as a front-line endovascular procedure.

MATERIALS AND METHODS: We analyzed 243 consecutive patients with large intracranial artery occlusions of the anterior circulation, treated within 6 hours with mechanical thrombectomy by either ADAPT or the Solitaire stent. The primary outcome was complete recanalization (modified TICI ≥ 2b); secondary outcomes included complication rates and procedural and clinical outcomes.

RESULTS: From November 2012 to June 2014, 119 patients were treated with stent retriever (Solitaire FR) and 124 by using the ADAPT with Penumbra reperfusion catheters. The median baseline NIHSS score was the same for both groups (Solitaire, 17 [interquartile range, 11–21] versus ADAPT, 17 [interquartile range, 12–21]). Time from groin puncture to recanalization (Solitaire, 50 minutes [range, 25–80 minutes] versus ADAPT, 45 minutes [range, 27–70 minutes], P = .42) did not differ significantly. However, compared with the Solitaire group, patients treated with ADAPT achieved higher final recanalization rates (82.3% versus 68.9%; adjusted relative risk, 1.18; 95% CI, 1.02–1.37; P = .022), though differences in clinical outcomes between the cohorts were not significant. Use of an adjunctive device was more frequent in the ADAPT group (45.2% versus 13.5%, P < .0001). The rate of embolization in new territories or symptomatic hemorrhage did not differ significantly between the 2 groups.

CONCLUSIONS: Front-line ADAPT achieved higher recanalization rates than the Solitaire device. Further randomized controlled trials are warranted to define the best strategy for mechanical thrombectomy.

ABBREVIATIONS: ADAPT — A Direct Aspiration, First Pass Technique for the Endovascular Treatment of Stroke; MT — mechanical thrombectomy; mTICI — modified TICI

Mechanical thrombectomy (MT) has now been validated through several large randomized controlled trials in the treatment of acute ischemic stroke due to large-vessel occlusion.1-3 These studies demonstrated a major decrease in disability. Successful revascularization has been shown to increase the likelihood of a good clinical outcome.6 However, these randomized controlled trials, by using the latest generation of stent retriever devices available at the time, reported successful revascularization rates ranging between 58% and 72% in the 2 largest studies.1,3 Although the randomized controlled trials proved that MT was beneficial, more than one-third of the procedures resulted in failure to recanalize.7,8 Improvement in the rate of successful recanalization is thus a critical issue. The stent retriever procedure starts with the common transfemoral access, followed by the introduction of the stent retrievers via a microcatheter through a balloon-guide catheter. The balloon-guide catheter is inflated to create
flow arrest while retrieving the stent retriever. Another approach is A Direct Aspiration, First Pass Technique for the Endovascular Treatment of Stroke (ADAPT), which involves using front-line aspiration alone to remove the thrombus through a highly trackable, atraumatic, large-bore aspiration catheter. Its success is based on using the largest catheter permitted by the vessel, ensuring greater aspiration power for thrombus extraction. In case of failure with the front-line ADAPT approach, the large-bore aspiration catheter can be used as a conduit for introducing a stent retriever or another adjunctive device; the system is thus versatile.

We aimed to compare the recanalization efficiency, clinical outcome, and complication rate of ADAPT and stent retrievers, 2 strategies of mechanical thrombectomy.

MATERIALS AND METHODS
A prospective clinical registry was used to consecutively identify and analyze patients with acute ischemic stroke treated at 2 comprehensive stroke centers between November 2012 and June 2014 (EFFECTS Registry, Endovascular Treatment at Foch Hospital-Rothschild Foundation in Ischemic Stroke). All patients were assessed for the presence of large intracranial artery occlusions of the anterior circulation and received front-line MT by using either the Solitaire (Covidien, Irvine, California) device or ADAPT by using the 5MAX or 5MAX ACE Reperfusion Catheter (Penumbra, Alameda, California) (On-line Appendix). Most patients underwent brain MR imaging in the acute phase. In cases of MR imaging contraindications, brain CT and CT angiography were performed.

Standard Protocol Approvals
Locally ethics committees and French Data Protection Agency approved the use of patient data for this retrospective analysis.

Inclusion and Exclusion Criteria
The following criteria were required for inclusion in this study:

- Proximal middle cerebral artery occlusion or intracranial internal carotid artery occlusion, without associated cervical internal carotid artery occlusion/critical stenosis, was present. Patients referred for acute ischemic stroke with cervical internal carotid occlusion/critical stenosis and basilar occlusion were excluded from this study to decrease bias due to the heterogeneity of patients and endovascular approaches.

- Patients were eligible if they were treatable by MT within 6 hours of stroke onset, with bridging therapy (previous IV rtPA) or stand-alone thrombectomy. The interventional neuroradiologist could, in the case of recanalization failure (modified TICI [mTICI] < 2b) with the ADAPT or the Solitaire system, use another thrombectomy device of the operator’s choice (rescue therapy).

Data Collection and Definitions
Information on patient characteristics, medical history, laboratory and imaging findings, vital signs before treatment, severity of ischemic stroke, and clinical outcome was collected prospectively by using the same structured questionnaire. The severity of the ischemic stroke was assessed by using the NIHSS score at admission and 24 hours later. We defined early neurologic improvement as an NIHSS score of 0–1 at 24 hours or a decrease of at least 4 points in the NIHSS score. Good functional outcome was defined as a 90-day mRS score of ≤2. Excellent outcome was defined as a 90-day mRS score of ≤1. All patients underwent a CT or MR imaging 24 hours after treatment to assess hemorrhagic complications. Symptomatic intracranial hemorrhage was defined according to the ECASS-II (European Co-operative Acute Stroke Study-II) definition: any intracerebral hemorrhage with an increase of at least 4 NIHSS points within 24 hours, or resulting in death. Symptomatic intracranial hemorrhage was assessed in a blinded manner by noninvolved senior neuroradiologists (R.B., H.R.) and vascular neurologists (B.L., J.-P.D.). The blinded assessment of symptomatic intracranial hemorrhage was specifically performed for this study to assess both aspects of mechanical thrombectomy (successful recanalization rate and hemorrhage complications). During the MT procedure, the presence of embolization in a new territory (defined as an angiographic occlusion in a previously unaffected vascular territory observed on the angiogram after clot removal), the time from symptom onset to groin puncture and from groin puncture to maximal mTICI, and the mTICI score were also monitored. The modified Rankin Scale score at 90 days was assessed by trained research nurses unaware of the study group assignments, during face-to-face interviews or via telephone conversations.

Endovascular Procedure
ADAPT Group. Patients received aspiration thrombectomy by ADAPT by using the 5MAX ACE (Penumbra) as front-line therapy. The detailed technical procedure has been published previously. In brief, access was achieved through the femoral artery in compliance with the standard of care. Large-bore catheters were placed distally into the internal carotid artery to provide access for the 5MAX ACE aspiration catheter. Adhering to the instructions for use, the 5MAX ACE catheter was advanced to the level of the occlusion over a microcatheter and a microguidewire. Continuous aspiration was then performed by using the Penumbra aspiration pump for at least 90 seconds in all cases. After engagement of the thrombus with the aspiration catheter, the catheter was allowed to aspirate for at least 30 seconds before its withdrawal with the engaged thrombus. Angiography was performed following recovery to evaluate the flow rate. The preceding steps were repeated until successful revascularization to mTICI 2b–3 was achieved, while adhering to the admissible treatment window (<6 hours from stroke onset). The interventional neuroradiologist could, in the case of recanalization failure (mTICI < 2b) with ADAPT, use another thrombectomy device of the operator’s choice (rescue therapy).

Solitaire Group. All MT procedures were performed by using the Solitaire FR (Covidien) via the femoral artery approach. Following the instructions for use of the Solitaire FR, a balloon catheter was positioned within the internal carotid artery to allow flow arrest during thrombus retrieval. The Solitaire FR device was delivered through a microcatheter and deployed inside the thrombus. A control angiogram was performed to determine the immediate reperfusion status, and the device was left deployed for a minimum of 3 minutes. Before retrieval of the stent retriever, the
when the expected cell frequency was 1862 were performed between the ADAPT and Solitaire groups by using histograms and the Shapiro-Wilk test. Bivariate comparisons of categorical variables. Normality of distributions was assessed by using non-Gaussian distributions). Differences in primary and secondary outcomes were further adjusted for baseline differences (at $P < .20$ in bivariate analyses) by using a Poisson regression model with robust error variance. Statistical testing was performed at the 2-tailed $\alpha$ level of .05 except for tests of heterogeneity in which an $\alpha$ level of .10 was chosen. Data were analyzed by using SAS software, Version 9.3 (SAS Institute, Cary, North Carolina).

**TABLE 1: Baseline characteristics in patients with acute ischemic stroke treated by ADAPT or a conventional stent retriever front-line approach$^a$**

<table>
<thead>
<tr>
<th></th>
<th>Solitaire Group (n = 119)</th>
<th>ADAPT Group (n = 124)</th>
<th>$P$ Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (yr) (mean)</td>
<td>65.5 ± 14.7</td>
<td>64.3 ± 15.7</td>
<td>.52</td>
</tr>
<tr>
<td>Men</td>
<td>55 (46.2)</td>
<td>61 (49.1)</td>
<td>.64</td>
</tr>
<tr>
<td>Medical history</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypertension</td>
<td>56 (47.5)</td>
<td>72 (59.0)</td>
<td>.073</td>
</tr>
<tr>
<td>Diabetes</td>
<td>7 (5.9)</td>
<td>21 (17.2)</td>
<td>.007</td>
</tr>
<tr>
<td>Hypercholesterolemia</td>
<td>31 (26.3)</td>
<td>32 (26.2)</td>
<td>.99</td>
</tr>
<tr>
<td>Current smoking</td>
<td>20 (18.4)</td>
<td>27 (22.1)</td>
<td>.48</td>
</tr>
<tr>
<td>Antithrombotic therapy</td>
<td>43 (36.1)</td>
<td>44 (35.8)</td>
<td>.95</td>
</tr>
<tr>
<td>NIHSS score (mean)</td>
<td>15.9 ± 6.1</td>
<td>15.9 ± 6.5</td>
<td>.99</td>
</tr>
<tr>
<td>ASPECTS value at admission (median) (IQR)</td>
<td>8 (7–10)</td>
<td>9 (8–10)</td>
<td>.64</td>
</tr>
<tr>
<td>Occlusion site</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ICA (isolated or tandem with MCA)</td>
<td>32 (26.9)</td>
<td>38 (30.7)</td>
<td>.52</td>
</tr>
<tr>
<td>Isolated MCA</td>
<td>87 (73.1)</td>
<td>86 (69.3)</td>
<td>.001</td>
</tr>
<tr>
<td>Previous use of IV thrombolysis</td>
<td>54 (45.4)</td>
<td>82 (66.1)</td>
<td>.001</td>
</tr>
<tr>
<td>Onset-to-groin puncture time (min) (median) (IQR)</td>
<td>235 (181–300)</td>
<td>247 (206–308)</td>
<td>.18</td>
</tr>
</tbody>
</table>

*Note:*—IQR indicates interquartile range.

$^a$ Values are expressed as number (percentages) unless otherwise indicated.

Successful Recanalization and MT Approaches

Overall, 184 patients (75.7%) achieved a successful revascularization within a median duration of 45 minutes (interquartile range, 26–73) from groin puncture. In univariate analysis, successful revascularization at final angiography was significantly more often achieved in patients treated with ADAPT (82.3%) as opposed to the front-line stent retriever approach (68.9%) ($P = .015$) (Table 2). We found no significant heterogeneity in between-group differences across centers ($P = .62$, On-line Figure). After adjustment for baseline differences, the ADAPT approach remained associated with a significant relative increase of 18% (95% CI, 2%–37%) in successful revascularization. Notably, a higher rate of use of additional devices occurred in the ADAPT group, 45.2% ($n = 56$), versus 13.5% ($n = 16$) in the Solitaire group, ($P < .0001$, On-line Table). The success rate (TICI 2b–3) of the 56 patients treated by ADAPT first-line and rescue therapy was 39/56 (69.6%). However, we found no significant difference in time between groin puncture and recanalization according to the MT procedure (Figure).
and 53.0% (n = 61) in the ADAPT group. A total of 46 deaths and 10 symptomatic intracerebral hemorrhages occurred, with no evidence of a difference between the 2 MT approaches (Table 2). Embolization to a new territory caused by MT occurred in 5.7% (n = 7) in the ADAPT group and 6.8% (n = 8) in the Solitaire group (P = .70).

**DISCUSSION**

Mechanical thrombectomy by using the latest generation devices has revolutionized the treatment of acute ischemic stroke, in part because the final rate of complete revascularization is higher than the historical rate.7,15,16 Successful reperfusion has been correlated with favorable outcomes.3,6,15,17-22 To the authors’ knowledge, no studies comparing ADAPT with stent retrievers have been previously published. Assessment of new revascularization strategies is needed to understand how to optimize thrombectomy procedures.

We found that front-line MT by the ADAPT approach achieved a higher rate of complete revascularization at final angiography than a front-line stent retriever–based strategy (82.3% versus 68.9%, adjusted P = .022). The use of adjunctive devices was higher in the ADAPT group than in the Solitaire group (ADAPT, 38.7%; versus Solitaire, 13.3%). Most interesting, this higher rate of adjunctive device use in the ADAPT group did not impact the groin puncture-to-recanalization time (P = .42, Fig 1). The benefit of the front-line ADAPT strategy is thus mainly derived from a higher percentage of rescue therapy. One explanation may be related to the ease of setting up a stent retriever through the large-bore aspiration catheter (Solumbra technique). Starting with a 5MAX ACE, required for the ADAPT technique, thus provides a versatile platform that can readily incorporate devices with different mechanisms of action.

Although the rate of revascularization in the ADAPT cohort was higher, the clinical outcomes did not differ from those in the Solitaire group. This outcome should be interpreted with caution given the comparative observational design of the study.

Periprocedural embolization to a new territory is a concern when performing a mechanical thrombectomy procedure. No differences in rates of embolization in a new territory between ADAPT (5.7%) and stent retriever (6.8%) front-line strategies were observed. However, our sample size was limited; experimental work suggests that a combined strategy with aspiration with adjunct stent retrievers may decrease the rate of embolization in a new territory.23

Symptomatic hemorrhagic complications, defined in this study as an ECASS-evident intracranial hemorrhage with an increase of ≥4 on the NIHSS scale at 24 hours, were higher after the ADAPT approach. Study results yielded symptomatic intracranial hemorrhage rates (2.4% for ADAPT versus 5.9% for Solitaire) similar to those of recent randomized controlled trials studying stroke.1-5 Retrospective studies have reported a high rate of revascularization (TICI 2b/3 > 90%) with the ADAPT approach, with low complication rates such as 2% embolization in a new territory and no incidence of symptomatic intracranial hemorrhage.24,25

The imbalance of prior rtPA use, which was higher in the ADAPT group (66.1% versus 45.4% in the Solitaire group), may have impacted the rate of successful recanalization. However, the adjusted analysis for all confounding factors, including rtPA use, confirms the higher rate of recanalization in the ADAPT group. The direct effect of rtPA use with adjunctive MT remains controversial.26

---

**Table 2: Outcomes in ADAPT or Solitaire group**

<table>
<thead>
<tr>
<th>Outcomesa</th>
<th>Solitaire Group (n = 119)</th>
<th>ADAPT Group (n = 124)</th>
<th>Relative Risk</th>
<th>P Value</th>
<th>Relative Riskb</th>
<th>P Valueb</th>
</tr>
</thead>
<tbody>
<tr>
<td>Successful revascularization at final angiogram</td>
<td>82 (68.9)</td>
<td>102 (82.3)</td>
<td>1.19 (0.93–1.48)</td>
<td>.015</td>
<td>1.18 (0.92–1.53)</td>
<td>.182</td>
</tr>
<tr>
<td>Early neurologic improvement</td>
<td>61 (55.5)</td>
<td>56 (45.1)</td>
<td>1.03 (0.81–1.32)</td>
<td>.81</td>
<td>1.00 (0.78–1.28)</td>
<td>.99</td>
</tr>
<tr>
<td>90-day excellent outcome</td>
<td>44 (38.3)</td>
<td>45 (39.1)</td>
<td>1.02 (0.83–1.24)</td>
<td>.89</td>
<td>1.10 (0.78–1.46)</td>
<td>.58</td>
</tr>
<tr>
<td>90-day favorable outcome</td>
<td>63 (54.6)</td>
<td>61 (53.0)</td>
<td>0.97 (0.76–1.23)</td>
<td>.79</td>
<td>1.05 (0.82–1.35)</td>
<td>.70</td>
</tr>
<tr>
<td>90-day mortality</td>
<td>20 (17.4)</td>
<td>26 (22.6)</td>
<td>1.30 (0.77–2.19)</td>
<td>.32</td>
<td>1.14 (0.64–2.01)</td>
<td>.65</td>
</tr>
<tr>
<td>ENT</td>
<td>8 (6.8)</td>
<td>7 (5.7)</td>
<td>–</td>
<td>.70</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>sICH</td>
<td>7 (5.9)</td>
<td>3 (2.4)</td>
<td>–</td>
<td>.21</td>
<td>–</td>
<td>–</td>
</tr>
</tbody>
</table>

*Note:* ENT indicates embolization in a new territory rate; sICH, symptomatic intracranial hemorrhage.

a Early neurologic improvement is defined as an NIHSS score 0–1 at 24 hours or a decrease of ≥4 points in NIHSS scores at 24 hours. Excellent outcome is defined as an mRS score of ≤1, favorable outcome, an mRS score of ≤2; and successful recanalization, an mTICI score of 2b–3 at final angiography.

b Adjusted for between-group differences in hypertension, diabetes, prior IV thrombolysis, and onset-to-groin puncture time (calculated with a robust Poisson regression model).
The present findings are derived from observational analyses, which are subject to well-known limitations. The first is the potential for confounding by measured or unmeasured variables, which cannot be ruled out, even after adjustment for baseline between-group differences. The second concerns the potential evaluation bias in clinical outcomes in the absence of blinded evaluation. In addition, no formal study sample size was calculated, and we could not exclude some differences being overlooked due to the lack of adequate statistical power. In a posteriori power calculation (not taking into account the adjustment), we calculated the smallest significant between-group difference (expressed as effect size by using relative risk) that our study sample size allowed us to detect with a power of 80%. Assuming an incidence of good outcome of 10% and 50% in the reference group (Solitaire), we could respectively detect a relative risk of 2.34 and 1.35 (or 0.43 and 0.74 for a detrimental effect).

We suggest that future studies follow a randomized controlled trial with core imaging performed by an independent neurointerventionalist to further support those findings.

We are currently starting the Interest of Direct Aspiration First Pass Technique (ADAPT) for Thrombectomy Revascularisation of Large Vessel Occlusion in Acute Ischaemic Stroke trial, a randomized, controlled, multicentric, blinded-end-point study (ClinicalTrials.gov, NCT02523261).

CONCLUSIONS

Front-line ADAPT as an MT strategy achieved higher recanalization rates compared with the Solitaire device, though ADAPT versus stent retriever in acute ischemic stroke; results of the MERCI Trial of Large Vessel Occlusion in Acute Ischaemic Stroke (SWIFT) trial with core imaging performed by an independent neurointerventionalist to further support those findings.

We suggest that future studies follow a randomized controlled trial with core imaging performed by an independent neurointerventionalist to further support those findings. We are currently starting the Interest of Direct Aspiration First Pass Technique (ADAPT) for Thrombectomy Revascularisation of Large Vessel Occlusion in Acute Ischaemic Stroke trial, a randomized, controlled, multicentric, blinded-end-point study (ClinicalTrials.gov, NCT02523261).

ACKNOWLEDGMENTS

We thank Mary Osborne-Pellegrin for help in editing the final draft of the manuscript.

Disclosures: Bertrand Lapergue—RELATED: Grant; An institutional grant has been provided by Penumbra for ASTER TRIAL (ADAPT versus stent retriever in acute ischemic stroke); Support for Travel to meetings for the study or other purposes: travel support by Medtronic; Payment for lectures (including service of Speakers Bureau) speaker’s honoraria from Penumbra. Bruno Bartolini—UNRELATED: Consultancy: Stryker Neurovascular. Michel Mazighi—UNRELATED: Consultancy: Servier. Comments: honoraria for teaching engagements as a consultant. Payment for Lectures (including service on Speakers Bureau): Covidien. Travel/Accommodations/Meeting Expenses Unrelated to Activities Listed: Bayer A.G., Boehringer Ingelheim, Covidien. Michel Piotin—UNRELATED: Consultancy: Medtronic.* Stryker.* MicroVention.* Penumbra.* Payment for Lectures (including service on Speakers Bureau): Medtronic.* Penumbra.* Grants/grants pending: institutional grants from Stryker, Medtronic, MicroVention, Balt. OTHER: institutional grant from Medtronic for training and proctoring physicians using Pipeline. Raphael Blanc—UNRELATED: Grants/grants pending: institutional grants from Stryker, Medtronic, MicroVention, Balt. OTHER: institutional grant from Medtronic for training and proctoring physicians using Pipeline. *Money paid to the institution.

REFERENCES

21. Tomssick T, Broderick J, Carrozza J, et al; Interventional Management of Stroke II Investigators. Revascularization results in the In-